BUB1B: A Potential Drug Target and Biomarker (G701)

Target Name: BUB1B

NCBI ID: G701

BUB1B

BUB1B: A Potential Drug Target and Biomarker

Bub1A, also known as BUB1B, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the BCL-2 family of proteins, which are known for their role in regulating cell growth and survival. Several studies have suggested that BUB1A may have potential as a drug target or biomarker, and further research is needed to determine its full potential.

Potential Drug Target

One of the most promising aspects of BUB1A is its potential as a drug target. The BCL-2 family of proteins has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BUB1A has been shown to play a role in the regulation of cell growth and survival, and its potential as a drug target is based on its ability to interact with various signaling pathways.

Several studies have shown that BUB1A can interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. These interactions suggest that BUB1A may be a target for drugs that are designed to inhibit its activity. One potential drug that may target BUB1A is the small molecule inhibitor, BHQ-155, which is currently being tested in clinical trials for the treatment of various cancers.

BioMarker

In addition to its potential as a drug target, BUB1A may also be a useful biomarker for certain diseases. The BCL-2 family of proteins has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. BUB1A has been shown to be expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract.

One potential use for BUB1A as a biomarker is its ability to be used as a target for diagnostic tests. The expression of BUB1A in various tissues makes it a potential target for diagnostic tests that are designed to detect the protein in those tissues. For example, BUB1A has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its levels have been used as a diagnostic marker for this disease.

Conclusion

In conclusion, BUB1A is a protein that has been shown to play a role in the regulation of cell growth and survival. Its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to determine the full potential of BUB1A as a drug and biomarker, and to explore its potential as a treatment for various diseases.

Protein Name: BUB1 Mitotic Checkpoint Serine/threonine Kinase B

Functions: Essential component of the mitotic checkpoint. Required for normal mitosis progression. The mitotic checkpoint delays anaphase until all chromosomes are properly attached to the mitotic spindle. One of its checkpoint functions is to inhibit the activity of the anaphase-promoting complex/cyclosome (APC/C) by blocking the binding of CDC20 to APC/C, independently of its kinase activity. The other is to monitor kinetochore activities that depend on the kinetochore motor CENPE. Required for kinetochore localization of CENPE. Negatively regulates PLK1 activity in interphase cells and suppresses centrosome amplification. Also implicated in triggering apoptosis in polyploid cells that exit aberrantly from mitotic arrest. May play a role for tumor suppression

The "BUB1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BUB1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets